- Home
- MNOV vs MGX Comparison
MNOV vs MGX Comparison
Compare MNOV & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- MGX
- Stock Information
- Founded
- MNOV 2000
- MGX 2018
- Country
- MNOV United States
- MGX United States
- Employees
- MNOV N/A
- MGX N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- MGX
- Sector
- MNOV Health Care
- MGX
- Exchange
- MNOV Nasdaq
- MGX NYSE
- Market Cap
- MNOV 68.2M
- MGX 62.1M
- IPO Year
- MNOV 2005
- MGX 2024
- Fundamental
- Price
- MNOV $1.28
- MGX $2.24
- Analyst Decision
- MNOV Strong Buy
- MGX Strong Buy
- Analyst Count
- MNOV 2
- MGX 4
- Target Price
- MNOV $7.00
- MGX $13.00
- AVG Volume (30 Days)
- MNOV 17.6K
- MGX 921.5K
- Earning Date
- MNOV 08-07-2025
- MGX 08-13-2025
- Dividend Yield
- MNOV N/A
- MGX N/A
- EPS Growth
- MNOV N/A
- MGX N/A
- EPS
- MNOV N/A
- MGX N/A
- Revenue
- MNOV N/A
- MGX $45,263,000.00
- Revenue This Year
- MNOV N/A
- MGX N/A
- Revenue Next Year
- MNOV N/A
- MGX $11.75
- P/E Ratio
- MNOV N/A
- MGX N/A
- Revenue Growth
- MNOV N/A
- MGX N/A
- 52 Week Low
- MNOV $1.12
- MGX $1.23
- 52 Week High
- MNOV $2.55
- MGX $5.49
- Technical
- Relative Strength Index (RSI)
- MNOV 43.16
- MGX 70.08
- Support Level
- MNOV $1.32
- MGX $2.04
- Resistance Level
- MNOV $1.38
- MGX $2.47
- Average True Range (ATR)
- MNOV 0.04
- MGX 0.16
- MACD
- MNOV 0.00
- MGX 0.08
- Stochastic Oscillator
- MNOV 25.00
- MGX 72.64
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.